公开(公告)号：US20180258176A1

公开(公告)日：2018-09-13

申请号：US15978699

申请日：2018-05-14

Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.

Inventor： Hans van Eenennaam ,  Andrea van Elsas ,  David Lutje Hulsik ,  Jan Paul Medema

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/564 ,  G01N33/574

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/564 ,  G01N33/57488 ,  G01N2800/24

Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.

公开(公告)号：US10072087B2

公开(公告)日：2018-09-11

申请号：US15849743

申请日：2017-12-21

Applicant: HOFFMANN-LA-ROCHE INC.

Inventor： Nikolaos Dimoudis ,  Georg Fertig ,  Alexander Fidler ,  Guy Georges ,  Klaus Kaluza ,  Martin Lanzendoerfer ,  Carola Ries ,  Stefan Seeber ,  Marlene Thomas

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20180251561A1

公开(公告)日：2018-09-06

申请号：US15760193

申请日：2016-10-07

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ,  University of Maryland, College Park

Inventor： Scott Durum ,  Julie Hixon ,  Wen Qing Li ,  Scott Walsh ,  Lila Kashi

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574

CPC classification number: C07K16/2866 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/2809 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/7155

Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7Rα are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7Rα using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7Rα, such as acute lymphoblastic leukemia.

公开(公告)号：US20180244805A1

公开(公告)日：2018-08-30

申请号：US15963221

申请日：2018-04-26

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Junichi NEZU ,  Atsushi NARITA ,  Takahiro ISHIGURO ,  Mika SAKURAI ,  Hirotake SHIRAIWA ,  Naoka HIRONIWA ,  Tomoyuki IGAWA ,  Yumiko KAWAI

IPC: C07K16/46 ,  C07K16/30

CPC classification number: C07K16/468 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/303 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C12N5/10 ,  C12N15/09

Abstract: Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.

公开(公告)号：US20180244788A1

公开(公告)日：2018-08-30

申请号：US15875530

申请日：2018-01-19

Applicant: HOFFMANN-LA ROCHE INC.

Inventor： Nikolaos DIMOUDIS ,  Georg FERTIG ,  Alexander FIDLER ,  Klaus KALUZA ,  Marlene THOMAS ,  Carola RIES ,  Stefan SEEBER ,  Martin LANZENDOERFER (DECEASED)

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US10047158B2

公开(公告)日：2018-08-14

申请号：US15895741

申请日：2018-02-13

Applicant: Genentech, Inc.

Inventor： Jane L. Grogan ,  Robert J. Johnston ,  Yan Wu ,  Wei-Ching Liang ,  Patrick Lupardus ,  Mahesh Yadav ,  Dhaya Seshasayee ,  Meredith Hazen

IPC: C07K16/00 ,  C07K16/28 ,  A61K38/17 ,  A61K45/06 ,  A61K39/395 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K38/177 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2878 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/70 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/466

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

公开(公告)号：US20180224447A1

公开(公告)日：2018-08-09

申请号：US15787234

申请日：2017-10-18

Applicant: Institute of Arthritis Research, LLC

Inventor： Craig D. Scoville

IPC: G01N33/564 ,  C07K16/28 ,  C07K7/06 ,  C07K14/435 ,  C07K16/18 ,  C07K7/08

CPC classification number: G01N33/564 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K16/18 ,  C07K16/2896 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76

Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.

公开(公告)号：US20180222964A1

公开(公告)日：2018-08-09

申请号：US15749210

申请日：2016-07-29

Applicant: GlaxoSmithKline Intellectual Property Developmant Limited

Inventor： Valeriu DAMIAN ,  Austin Keith DOYLE ,  Laura Maria HALO ,  Emma R. HARDING ,  Xuan HONG ,  Alan Peter LEWIS ,  Mark UDEN

IPC: C07K16/00

CPC classification number: C07K16/00 ,  A61K2039/54 ,  C07K2317/567 ,  C07K2317/94

Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.

公开(公告)号：US10035861B2

公开(公告)日：2018-07-31

申请号：US14552289

申请日：2014-11-24

Applicant: Amgen Inc.

Inventor： Frank J. Calzone ,  Rajendra V. Deshpande ,  Mei-Mei Tsai

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/22 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

公开(公告)号：US10035854B2

公开(公告)日：2018-07-31

申请号：US15349757

申请日：2016-11-11

Applicant: Genentech, Inc.

Inventor： Yan Wu ,  Weilan Ye ,  Jeremy Bryant Burton ,  Cecilia Chiu

IPC: A61P9/10 ,  A61P27/02 ,  A61K39/395 ,  C07K16/28 ,  C07H21/04 ,  A61K47/68 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/395 ,  A61K47/6849 ,  A61K2039/505 ,  A61P9/10 ,  A61P27/02 ,  C07H21/04 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/75 ,  C07K2317/92

Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.